Abstract
Management of locally advanced soft tissue sarcomas (STS) of the extremities that leads to an increase in preservation of functional limb continues to be a challenge. Isolated limb perfusion (ILP) with TNF-α and melphalan is a locoregional approach for advanced soft tissue sarcomas that has proved to be very effective to achieve this goal. The most prominent antineoplastic effect of TNF-α involves tumor vascularization, owing to early and selective alterations in tumor-associated endothelial cells, resulting in destruction of the tumor vessels. ILP may render a nonresectable tumor resectable and may reduce the local recurrence rate; in cases with widespread metastases, it can be used palliatively to avoid ablative surgery. ILP with TNF-α and melphalan has been shown to result in excellent response rates over 75% and to achieve long-term limb salvage rates in approx 80% of patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand 1994;259:1–31.
Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. Cancer J Clin 2001;51:15–36.
Hoekstra HJ, Schraffordt, Koops H, Oldhoff J. Soft tissue sarcoma of the extremity. Eur J Surg Oncol 1994;20:3–6.
Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12:1137–1149.
Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue extremity sarcomas: a muliticenter trial. Ann Surg 1996;224:756–765.
Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756–765.
Eggermont AMM, de Wilt JHW, ten Hagen TLM. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429–437.
Chang AE, Sondak VK. Clinical evaluation and treatment of soft tissue tumors, in Soft Tissue Tumors, 3rd ed. (Enzinger FM, Weiss SW, eds.), Mosby, St. Louis 1995;17–31.
Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985;3:353–366.
Lienard D, Delmotte JJ, Renard N, Ewalenko P, Lejeune FJ. High-dose recombinant tumor necrosis factor-alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52–60.
Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1959;148:616–632.
Lienard D, Eggermont AMM, Schraffordt Koops H, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491–502.
Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JHW, Eggermont AMM. One hundred consecutive isolated limb perfusions with TNF-α and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004;240:939–948.
Klaase JM, Kroon BBR, Benckhuysen C, van Geel AN, Albus-Lutter CE, Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989;64:616–621.
Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate of high grade limb sarcomas. Cancer 1994;73:2140–2146.
Wieberdink J, Benckhuijsen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905–910.
Carswell EA, Old LJ, Kassel RL. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666–3670.
Sidhu RS, Bollon AP. Tumor necrosis factor activities and cancer therapy—a perspective. Pharmacol Ther 1993;57:79–128.
de Wilt JHW, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AMM. Tumour necrosis factor alpha increases melphalan concentration in tumor tissue after isolated limb perfusion. Br J Cancer 2000;82:1000–1003.
Vrouenraets BC, Kroon BBR, Ogilvie AC, et al. Absence of severe systemic toxicity after leakagecontrolled isolated limb perfusion with tumor necrosis factor-α and melphalan. Ann Surg Oncol 1999;6:405–412.
Olieman AFT, vanGinkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Hyperthermic isolated limb perfusion with tumor necrosis factor-α and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile? Arch Orthop Trauma Surg 1998;118:70–74.
Olieman AFT, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Lejeune F. The angiographic response of locally advanced soft tissue sarcomas following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997;4:64–69.
Eggermont AMM, ten Hagen TLM. Isolated limb perfusion for extremity soft-tissue sarcomas, intransit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 2001;3:359–367.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Schlag, P.M., Tunn, PU. (2007). Isolated Limb Perfusion in Advanced Soft Tissue Sarcomas. In: Schlag, P.M., Stein, U., Eggermont, A.M.M. (eds) Regional Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-225-0_25
Download citation
DOI: https://doi.org/10.1007/978-1-59745-225-0_25
Publisher Name: Humana Press
Print ISBN: 978-1-58829-672-6
Online ISBN: 978-1-59745-225-0
eBook Packages: MedicineMedicine (R0)